OGN News and Press, Organon & Co. From 02/22/24

2024-02-22 11:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary. HADLIMA is an FDA-approved biosimilar to HUM...

2024-02-16 11:45:57 ET Summary Organon's Q4 earnings report led to a surge in share price, reaching a 6-month high of $18. FY revenues were $6.2bn, and adjusted EBITDA $1.9bn. The company's focus on developing new revenue streams in Women's Health and Biosimilars is starting to sh...

2024-02-15 12:06:05 ET Organon & Co. (OGN) Q4 2023 Earnings Conference Call February 15, 2024, 08:30 AM ET Company Participants Jennifer Halchak - Vice President of Investor Relations Kevin Ali - CEO & Director Matthew Walsh - Executive VP & CFO ...

2024-02-15 11:33:25 ET More on Organon Organon & Co. 2023 Q4 - Results - Earnings Call Presentation Organon & Co. (OGN) JPMorgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 Organon beats top-li...

2024-02-15 07:50:53 ET More on Organon Organon & Co. (OGN) JPMorgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued Orga...

2024-02-15 07:32:28 ET More on Organon Organon & Co. (OGN) JPMorgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued Orga...

Full year 2023 revenue of $6.3 billion, up 1% as-reported and 3% at constant currency Full year 2023 diluted earnings per share of $3.99 and non-GAAP Adjusted diluted earnings per share of $4.14 Full year 2023 Adjusted EBITDA of $1.9 billion, representing a 31.0% Adjusted EBITDA margin ...

Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...

2024-02-14 12:33:26 ET More on Organon Organon & Co. (OGN) JPMorgan 42nd Annual Healthcare Conference (Transcript) Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued Orga...